These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 20215136)

  • 1. Treatment with the mTOR inhibitor temsirolimus in patients with malignant PEComa.
    Italiano A; Delcambre C; Hostein I; Cazeau AL; Marty M; Avril A; Coindre JM; Bui B
    Ann Oncol; 2010 May; 21(5):1135-7. PubMed ID: 20215136
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell tumors: targeting the pathogenic activation of mTORC1 in tumors.
    Wagner AJ; Malinowska-Kolodziej I; Morgan JA; Qin W; Fletcher CD; Vena N; Ligon AH; Antonescu CR; Ramaiya NH; Demetri GD; Kwiatkowski DJ; Maki RG
    J Clin Oncol; 2010 Feb; 28(5):835-40. PubMed ID: 20048174
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination targeted therapy of VEGFR inhibitor, sorafenib, with an mTOR inhibitor, sirolimus induced a remakable response of rapid progressive Uterine PEComa.
    Gao F; Huang C; Zhang Y; Sun R; Zhang Y; Wang H; Zhang S
    Cancer Biol Ther; 2016 Jun; 17(6):595-8. PubMed ID: 27030639
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of Advanced Malignant Uterine Perivascular Epithelioid Cell Tumor with mTOR Inhibitors: Single-institution Experience and Review of the Literature.
    Starbuck KD; Drake RD; Budd GT; Rose PG
    Anticancer Res; 2016 Nov; 36(11):6161-6164. PubMed ID: 27793946
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [mTOR and non-small cell lung cancer].
    Wang L; Xu S; Yue W
    Zhongguo Fei Ai Za Zhi; 2010 Jan; 13(1):69-72. PubMed ID: 20672708
    [No Abstract]   [Full Text] [Related]  

  • 6. A rare metastatic mesenteric malignant PEComa with TSC2 mutation treated with palliative surgical resection and nab-sirolimus: a case report.
    Meredith L; Chao T; Nevler A; Basu Mallick A; Singla RK; McCue PA; Bowne WB; Jiang W
    Diagn Pathol; 2023 Apr; 18(1):45. PubMed ID: 37041531
    [TBL] [Abstract][Full Text] [Related]  

  • 7. First pancreatic perivascular epithelioid cell tumor (PEComa) treated by mTOR inhibitor.
    Gondran H; Thebaud E; Moreau A; Le Rhun M; Touchefeu Y; Regenet N; Musquer N
    Pancreatology; 2019 Jun; 19(4):566-568. PubMed ID: 31130397
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Temsirolimus.
    Stock C; Zaccagnini M; Schulze M; Teber D; Rassweiler JJ
    Recent Results Cancer Res; 2010; 184():189-97. PubMed ID: 20072839
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Resistance to mammalian target of rapamycin inhibitor therapy in perivascular epithelioid cell tumors.
    Subbiah V; Trent JC; Kurzrock R
    J Clin Oncol; 2010 Aug; 28(24):e415. PubMed ID: 20567010
    [No Abstract]   [Full Text] [Related]  

  • 10. New inhibitors of the mammalian target of rapamycin signaling pathway for cancer.
    Albert S; Serova M; Dreyer C; Sablin MP; Faivre S; Raymond E
    Expert Opin Investig Drugs; 2010 Aug; 19(8):919-30. PubMed ID: 20569080
    [TBL] [Abstract][Full Text] [Related]  

  • 11. mTOR inhibitors in polycystic kidney disease.
    Watnick T; Germino GG
    N Engl J Med; 2010 Aug; 363(9):879-81. PubMed ID: 20581393
    [No Abstract]   [Full Text] [Related]  

  • 12. A retrospective study of patients with malignant PEComa receiving treatment with sirolimus or temsirolimus: the Royal Marsden Hospital experience.
    Benson C; Vitfell-Rasmussen J; Maruzzo M; Fisher C; Tunariu N; Mitchell S; Al-Muderis O; Thway K; Larkin J; Judson I
    Anticancer Res; 2014 Jul; 34(7):3663-8. PubMed ID: 24982384
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Extrarenal perivascular epithelioid cell tumors (PEComas) respond to mTOR inhibition: clinical and molecular correlates.
    Dickson MA; Schwartz GK; Antonescu CR; Kwiatkowski DJ; Malinowska IA
    Int J Cancer; 2013 Apr; 132(7):1711-7. PubMed ID: 22927055
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Addition of Antiestrogen Treatment in Patients with Malignant PEComa Progressing to mTOR Inhibitors.
    Sanfilippo R; Fabbroni C; Fucà G; Fumagalli E; Morosi C; Sbaraglia M; Gronchi A; Collini P; Dei Tos AP; Casali PG
    Clin Cancer Res; 2020 Oct; 26(20):5534-5538. PubMed ID: 32605908
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [mTOR inhibitors: temsirolimus and everolimus in the treatment of renal cell carcinoma].
    Ravaud A; Bernhard JC; Gross-Goupil M; Digue L; Ferriere JM
    Bull Cancer; 2010; 97():45-51. PubMed ID: 20418203
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Malignant variant of sclerosing perivascular epithelioid cell tumor arising in the adnexa.
    Ramaiah S; Ganesan R; Mangham DC; McNally O; Klys HS; Hirschowitz L
    Int J Gynecol Pathol; 2009 Nov; 28(6):589-93. PubMed ID: 19851212
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Perivascular epithelioid cell tumor (PEComa) of the uterus with aggressive behavior at presentation.
    Liu JL; Lin YM; Lin MC; Yeh KT; Hsu JC; Chin CJ
    Hematol Oncol Stem Cell Ther; 2009; 2(3):426-30. PubMed ID: 20139058
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Temsirolimus for metastatic desmoplastic small round cell tumor.
    Thijs AM; van der Graaf WT; van Herpen CM
    Pediatr Blood Cancer; 2010 Dec; 55(7):1431-2. PubMed ID: 20730888
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neoadjuvant sirolimus for a large hepatic perivascular epithelioid cell tumor (PEComa).
    Bergamo F; Maruzzo M; Basso U; Montesco MC; Zagonel V; Gringeri E; Cillo U
    World J Surg Oncol; 2014 Feb; 12():46. PubMed ID: 24575738
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Successful treatment with the mTOR inhibitor everolimus in a patient with perivascular epithelioid cell tumor.
    Gennatas C; Michalaki V; Kairi PV; Kondi-Paphiti A; Voros D
    World J Surg Oncol; 2012 Sep; 10():181. PubMed ID: 22943457
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.